Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Among authors: florescu m. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB; Working Group on Economic Analysis; Lung Disease Site Group; National Cancer Institute of Canada Clinical Trials Group. Ng R, et al. Among authors: florescu m. J Clin Oncol. 2007 Jun 1;25(16):2256-61. doi: 10.1200/JCO.2006.09.4342. J Clin Oncol. 2007. PMID: 17538170 Clinical Trial.
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, Leighl N, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L. Melosky B, et al. Among authors: florescu m. Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1. Lung Cancer. 2019. PMID: 31200828 Clinical Trial.
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, Cohen V, Charbonneau C, Marcoux N, Blais N, Leighl NB, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Desilets A, et al. Among authors: florescu m. Eur J Cancer. 2021 Jan;142:83-91. doi: 10.1016/j.ejca.2020.10.008. Epub 2020 Nov 24. Eur J Cancer. 2021. PMID: 33242835
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: florescu m. J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36841541 Free article. Clinical Trial.
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: florescu m. J Thorac Oncol. 2024 Nov;19(11):1578-1579. doi: 10.1016/j.jtho.2024.08.017. Epub 2024 Aug 24. J Thorac Oncol. 2024. PMID: 39186030 No abstract available.
220 results